Insights
There is always something exciting happening at Lockton. Here are just a few from our newsroom.
GLP-1 Indications continue to expand: Potential approvals expected through 2026
Following other expanded indications for GLP-1s, Wegovy has now received FDA approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis. This marks a significant expansion in the …
New Lockton webcast series addresses the latest changes to leave law compliance
With 2026 quickly approaching, employers face an increasingly complex patchwork of new and amended state leave laws. To address these compliance challenges, Lockton is introducing its Fall 2025 Paid Leave Webcast Series, presented by our Integrated A …
Amidst continuous change, upcoming ERISA compliance webcasts keep employers in the know
This year has been an eventful one so far for health and welfare compliance, with a new presidential administration, the sweeping One Big Beautiful Bill Act, and several Supreme Court decisions, to name a few. For plan sponsors, it can be a lot to un …